Objective: To evaluate the safety and tolerability of PF-04494700, an oral inhibitor of receptor for advanced glycation end products, in patients with mild-to-moderate dementia of the Alzheimer type.
A lzheimer disease (AD) is a neurodegenerative disease, which is the leading cause of dementia in elderly people. 1, 2 It is characterized by the extracellular accumulation of b-amyloid (Ab) plaques consisting of Ab and Ab 1-40 peptides, and neurofibrillary tangles consisting of hyperphosphorylated tau protein filaments, accompanied by progressive cell loss, especially in cholinergic neurons in the basal forebrain region. 3, 4 There is increasing evidence that the accumulation of Ab peptides in the brain may play a pivotal role in the pathophysiological process of AD, 5 disrupting the synthesis and release of acetylcholine. 4 Available therapies for AD attempt to provide symptomatic relief through cholinergic mechanisms 6 or by altering N-methyl D-aspartate receptor mechanisms. 7 Currently, no disease modifying or antiamyloid therapies are available.
One promising disease modifying treatment strategy targets the receptor for advanced glycation end products (RAGE). RAGE is a multiligand receptor of the immunoglobulin superfamily, which is composed of 3 immunoglobulinlike domains: a "V"-type domain involved in ligand binding, and 2 "C"-type domains (a short transmembrane domain and a cytoplasmic tail involved in intracellular signaling). 8 RAGE is expressed in multiple cell types, and the receptor has been shown to bind to a broad array of ligands. It should be noted that RAGE recognizes not only specific amino acid sequences, but also 3-dimensional structures, such as b-sheets and fibrils. [8] [9] [10] Thus, RAGE seems to be a pattern recognition receptor, which binds ligands that typically accumulate in tissues during aging (including Ab peptide), inflammation, or in response to other tissue stresses. 8, [11] [12] [13] Ligands binding to RAGE have been shown to activate multiple cellular signaling cascades. In adults, RAGE is expressed at low levels in normal central nervous system (CNS) tissues. However, RAGE is rapidly upregulated in the presence of its ligands, most notably Ab. 8, 14 Accumulating evidence suggests that RAGE may play a significant role in the pathophysiology of AD. Data implicating RAGE include the identification of known RAGE ligands, including AGEs, S100b (a member of the superfamily of EF hand Ca 2+ binding proteins), and Ab proteins in tissue surrounding the senile plaque in humans. 15, 16 RAGE has also been reported to be upregulated in astrocytes and microglial cells in the hippocampus of individuals with AD compared with individuals who did not have AD. 17 Furthermore, inhibition of RAGE/ligand interactions, using either an sRAGE or an anti-RAGE antibody, reduces amyloid plaque formation in a mouse model of systemic amyloidosis. 18 PF-04494700 (earlier known as TTP488) is an orally bioavailable small molecule inhibitor of RAGE, which is being developed as a potential treatment for AD (and for diabetic nephropathy). In vitro studies have shown that PF-04494700 inhibits sRAGE from binding to RAGE ligands, S100b, amphoterin, and carboxymethyllysine (TransTech Internal Report). In addition, PF-04494700 has been shown, in a fluorescent polarization assay, to inhibit the binding of sRAGE to Ab (TransTech  Internal Report) .
In a mouse model of systemic amyloidosis, PF-04494700 reduced accumulation of Ab peptides in the spleen and the expression of interleukin (IL)-6 and macrophage colonystimulating factor. In a transgenic mouse model with Swedish and London mutations that overexpress human amyloid precursor protein, 90 days of treatment with orally administered PF-04494700 was associated with a significant reduction in both inflammatory markers [tumor necrosis factor-a, transforming growth factor TGF-b, and IL-1] and CNS amyloid deposition (TransTech Internal Report).
The results of initial phase 1 studies suggest that daily doses of PF-04494700 in the range of 10 to 60 mg/d administered orally for up to 4 weeks are safe and well tolerated in healthy volunteers. In 1 study (TTP488-102; data on file), 7 of 40 patients treated with PF-04494700 had a maximum increase of Z30 ms in QTcNi. The QTcNi values for 4 of these patients were Z450 ms. These findings were consistent with preclinical studies that found increases in QTc in dogs that were administered doses of Z10 mg/kg.
The primary objective of this study was to evaluate the safety and tolerability of short-term treatment with PF-04494700 in patients with mild-to-moderate AD. The secondary objectives were to assess the pharmacokinetic (PK) profile, and to evaluate the effect of short-term treatment with PF-04494700 on measures of cognitive function, and on plasma biomarkers related to the RAGE mechanism of action.
METHODS

Patients
Male or female outpatients were enrolled who were at least 50 years of age and who met the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association 19 criteria for probable AD of at least 1 year duration, with mild-to-moderate dementia [Mini-Mental State Examination (MMSE) 20 score of 12 to 26 at both the screening and baseline visit]. Additional inclusion criteria required that there be an adult informant who had significant direct contact with the patient on at least 3 days per week, and that a computed tomographic or magnetic resonance imaging scan was consistent with the diagnosis of AD, and showed no evidence of significant focal lesions or other pathology, which might account for dementia.
Exclusion criteria included: living alone or in a long-term care facility; a history within the previous 2 years of a neurological or psychiatric illness that could contribute to dementia; a history within the previous 3 years of Parkinson disease, seizure disorder, head injury with loss of consciousness, or meeting DSM IV criteria for any major psychiatric disorder; current (within the past year) history of poorly controlled hypertension, myocardial infarction, or unstable coronary artery disease; a QTc greater than 450 ms (female patients) or greater than 430 ms (male patients), or a family history of prolonged QT syndrome; a history in the last 2 years of symptomatic congestive heart failure, syncope, or recurrent hypokalemia; severe pulmonary disease; poorly controlled diabetes mellitus (hemoglobin A1C >9%); significant thyroid disease, unless euthyroid on treatment for at least 6 months; active neoplastic disease; clinically significant hematologic or coagulation disorder including any unexplained anemia or a platelet count <100,000 mL at screening; and clinically significant hepatic or renal disease, including the presence of hepatitis B or C antigen/antibody or an elevated transaminase level of greater than 2 times the upper limit of normal or creatinine greater than 1.5Â upper limit of normal. Excluded medications included: drugs known to significantly increase QTc and/or have increased risk of torsades de pointe, immunosuppressive agents, cancer chemotherapeutic agents; oral corticosteroids other than maintenance doses equivalent to 7.5 mg prednisone per day, and radiotherapy.
The study was conducted at 14 sites in the United States from October 2005 to June 2006, according to the Declaration of Helsinki and subsequent revisions, and approved by institutional review boards at each center. Before performing any study procedures, the patient (or their legally authorized representative if the patient was judged to be unable to provide informed consent) and the patient's informant read and signed an informed consent form.
Design
This was a 10-week, randomized, double-blind, placebo-controlled, parallel group study of the safety and tolerability of 2 dose regimens of PF-04494700 in patients who met criteria for AD that was mild-to-moderate in severity. After completing a 2-week screening phase, during which they were maintained on stable doses of their earlier prescribed AD treatments, patients were randomized to 1 of the 3 treatment groups: (1) a "low-dose" group (n=25) treated with PF-04494700 in a loading dose of 30 mg once daily for 6 days, followed by a 10 mg maintenance dose once daily for 63 days; (2) a "high-dose" group (n=25) treated with PF-04494700 in a loading dose of 60 mg once daily for 6 days, followed by a 20 mg maintenance dose once daily for 63 days; or (3) placebo (n=10). The reason for the loading dose was to quickly have the patients achieve steady state levels in this short-term trial. At the end of the 10-week, double-blind treatment period, study medication was discontinued and patients returned for a final end of study follow-up visit 4 weeks after the last dose. Patients who discontinued after randomization were not replaced.
Outcome Measures Safety
The primary objective of this study was to evaluate the safety and tolerability of PF-04494700 administered for 10 weeks in AD patients. All observed and volunteered adverse events were recorded, and rated as to severity, date of onset/ offset, and possible relationship with the studied drug. Safety measures also included laboratory tests (hematologies, chemistries, urinalysis), physical examination, vital signs, weight, and 12-lead electrocardiogram (ECG). Safety measures were obtained at the screening and baseline visits and at weeks 1, 2, 4, 6, 8, and 10 (or study endpoint). A 24 hours 12-lead serial ECG (Holter Monitor) was also obtained at baseline and week 10 (or study endpoint).
Efficacy
A secondary objective of the study was to evaluate the short-term effects of treatment with PF-04494700 on biomarkers in plasma related to the RAGE mechanism of action, consisting of the following: high sensitivity Creactive protein (hs-CRP; performed using a Roche CRP Latex particle-enhanced immunological agglutination assay), Ab (Ab 1-40 , Ab 1-42 ; performed by Pankaj D. Mehta, PhD, at the Institute for Basic Research in Developmental Disabilities, New York, NY using a double antibody sandwich enzyme-linked immunosorbent assay methodology), IL-b (using the human IL-1b immunoassay kit, Quantikine, R & D Systems), IL-6 (was performed on the DPC Immulite 2000 using a solid phase, enzyme-labeled chemiluminescent sequential immunometric assay), TGF-b1 (performed using a Quantikine Human TGF-b1 Immunoassay), and isoprostanes (performed by Domenico Pratico`at the University of Pennsylvania by negative ion chemical ionization gas chromatography mass spectrometry). Blood samples for biomarkers were collected at pretreatment baseline, weeks 4, and 10 (or endpoint).
Clinical and cognitive assessments were obtained at pretreatment baseline and at week 10 (or endpoint), and consisted of the MMSE, 20 Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), 21 Alzheimer's Disease Collaborative Study-Activities of Daily Living (ADCS-ADL), 22 and the Clinical Dementia Rating-Sum of Boxes (CDR-Sum of Boxes). 23 No prestudy investigator training or reliability assessment was made in the use of the clinical assessment tools.
PK
Blood samples to assess trough PF-04494700 concentrations were collected at pretreatment baseline, and at weeks 1, 2, 4, 6, 8, and 10 (or endpoint).
Statistical Analysis
As this was a pilot study of PF-04494700, designed to evaluate the safety and tolerability in patients with AD, no power was calculated. A total sample size of 60 patients was chosen based on clinical considerations and feasibility. All nonsafety efficacy endpoints were secondary, and only descriptive statistics were carried out. All analyses were carried out on the intent-to-treat sample, defined as all patients who were randomized to study treatment and had data from at least one postrandomization assessment available. As the primary objective of the study was to evaluate safety, if a patient terminated early, all week 10 efficacy assessments were made at that time point, and the results were carried forward to the subsequently missed time point analysis (last observation carried forward).
Descriptive statistics were also calculated for the PF-04494700 plasma concentration at each dosage level. Week 10 PF-04494700 plasma levels were used as the C min steady state value. If week 10 plasma concentrations were not available, then week 9 plasma concentrations were used. The trough plasma concentration was used to calculate mean plasma concentration versus time curves. The statistical software used in these analyses was SAS (Version 8.2; SAS Institute, Cary, NC).
RESULTS
Ninety-six patients were screened of whom 67 were randomized to study drug (Fig. 1) . The most common reasons for screen failure were failure to meet the AD severity criteria (N=11) and comorbid cardiovascular exclusions (N=8). A higher proportion of patients completed 10 weeks of double-blind treatment on both the 30/10 mg regimen of PF-04494700 (88.9%) and the 60/ 20 mg regimen (85.7%) than patients who were on placebo (66.7%; Fig. 1 ).
At baseline, the majority of patients in each treatment group were female candidates, with a mean age of approximately 75 years (Table 1 ). There were no clinically relevant between-group differences in baseline demographic or clinical characteristics. The mean MMSE score at baseline was consistent with AD of mild-to-moderate severity. Concomitant antidementia medications were used during the course of the study by 26 patients (92.6%) in the PF-04494700 60/20 mg dosage group, by 25 patients (92.6%) in the 30/10 mg dosage group, and by 10 patients (83.3%) in the placebo group. Other classes of concomitant medications, taken by greater than 20% of patients overall, included cholesterol-reducing and/or triglyceride-reducing drugs, nonsteroidal anti-inflammatory drug and non-nonsteroidal antiinflammatory drug analgesics, antithrombotic drugs, calcium supplements, b-blockers, and antidepressants.
Safety and Tolerability
Sixty-eight percent of patients treated with the 60/ 20 mg dose regimen of PF-04494700 experienced at least 1 adverse event compared with 67% of patients treated with the 30/10 mg dose regimen, and 75% of patients treated with placebo ( Table 2 ). The incidence of individual adverse events was low, with no dose-response trend evident. Among patients treated with the 60/20 mg dose regimen, 32% experienced an adverse event judged by the investigator to be possibly or probably related to study treatment, compared with 44% of patients treated with the 30/10 mg regimen, and 50% of patients treated with placebo.
A total of 6 (9.0%) patients withdrew from the study owing to an adverse event. Five of these 6 adverse events were judged by the investigator to be probably related and 1 event was judged to be possibly related to the study treatment. One patient discontinued from the 60/20 mg dose regimen owing to moderate agitation. Three patients discontinued from the 30/10 mg dose regimen, 1 owing to mild diarrhea and vomiting, 1 owing to severe vomiting, and 1 owing to mild diarrhea. Two patients discontinued from the placebo group; 1 owing to moderate pruritus and 1 owing to moderate hypomania.
There were 4 serious adverse events reported by 3 patients participating in this study. None of the events were judged to be related to the study treatment by the investigators. Three serious adverse events occurred in 2 patients on the 60/20 mg dose regimen. An 80-year-old White woman suffered 2 separate fractures of the left and right femoral necks, both requiring separate hospitalizations. The third serious event occurred in a 75-year-old White man hospitalized with a kidney stone. Finally, a 64year-old White woman in the placebo group experienced a seizure resulting in hospitalization. No serious adverse events occurred in the 30/10 mg dose regimen. There were no deaths during the study.
The incidence of clinically significant laboratory abnormalities was similar across study treatments; none were considered by the investigators to be related to study treatment. One patient treated in the 60/20 mg dosage group had an abnormal urinalysis (abnormal urine protein, red blood cells, and crystals), which occurred in the week after being diagnosed with a kidney stone. One patient in the 30/10 mg dosage group had abnormal aspartate aminotransferase, gamma-glutamyl transpeptidase, and lactate dehydrogenase values on treatment day 7. The gammaglutamyl transpeptidase and lactate dehydrogenase values had both been elevated at the screen visit, and had continued to be elevated throughout the double-blind treatment. The aspartate aminotransferase value was not elevated at the screen or baseline visits, and returned to normal on treatment day 14. Two patients in the placebo group had clinically significant abnormal laboratory tests. One patient had an abnormal urinalysis, which returned to normal on treatment day 42, except urine bacteria, which remained abnormal until the follow-up visit. The second patient had abnormal urinalysis results, which were also abnormal at the screen visit, and remained abnormal throughout the study. There were no consistent, dose-dependent, treatment emergent changes in the mean vital signs or ECG parameters during treatment with either the dose regimen of PF-04494700 or placebo. Four patients on PF-04494700 had ECG findings that were considered to be adverse events. A maximum on-treatment change in QTcB of greater than 30 ms was observed more frequently in patients treated with the 60/20 mg dose regimen (5, 19%) and the 30/10 mg dose regimen (7, 26%) than patients on placebo (0, 0%). No patients on the 60/20 mg dose regimen or placebo had a maximum on-treatment change in QTcB greater than 60 ms; one patient (4%) on the 30/10 mg dose regimen had an on-treatment change in QTcB greater than 60 ms.
PK Data
Blood samples were obtained for analysis of PF-04494700 plasma concentrations at each double-blind visit in the morning before the patient taking his or her once-daily dose. The concentration-time curve for this presumptive C min time point is shown in Figure 2 . As expected, the observed mean (SD) trough was higher for the 60 mg dosage group (42.4±17.7 ng/mL) than for the 30 mg dosage group (20.2±8.1 ng/mL). For patients on the 60 mg dose of PF-04494700, mean trough concentrations were higher in female patients versus male patients on days 7 (44.2±17.9 vs 40.0±18.1) and 70 (66.3±30.6 vs 44.7±25.2), respectively. Similarly, for patients on the 30 mg dose, mean trough concentrations were higher in female patients versus male patients on days 7 (22.6±8.0 vs 15.3±6.0) and 70 (28.5±12.2 vs 19.0±6.2), respectively.
Efficacy
At baseline, patients randomized to placebo had a somewhat greater impairment on both cognitive and functional measures when compared with patients randomized to both PF-04494700 dose regimens (Table 3) . No consistent or meaningful treatment effect was observed at week 10 on either PF-04494700 dose regimen in the MMSE, ADCS-ADL, ADAS-Cog, or CDR-Sum of Boxes.
At baseline, several inflammatory indices were either in the normal (IL-6) or low normal range (hs-CRP), although it should be noted that normative ranges have not been established for isoprostanes or TGG-b. Treatment with PF-04494700 was associated with a modestly greater reduction in isoprostanes at week 10 (Table 3 ). However, on other inflammatory markers there were no consistent treatment effects observed compared with placebo.
Patients treated with PF-04494700 had a small dosedependent increase in Ab 1-40 at week 10, whereas Ab 1-42 showed a small decrease ( Table 3 ). Inspection of week 10 values for individual patients found no consistent change from baseline trends in either Ab or Ab 1-42 levels.
DISCUSSION
Ten weeks of double-blind treatment with 2 dose regimens of PF-04494700 was found to be safe and well tolerated in patients with mild-to-moderate AD. The majority of adverse events observed during treatment with PF-04494700 were mild-to-moderate in intensity. Furthermore, there was a lower incidence on both dose regimens of PF-04494700 compared with placebo on 2 key tolerability measures, discontinuation owing to adverse events, and incidence of adverse events rated as severe. There was no dose-response effect, either in terms of the incidence of treatment-related adverse events, which were lower among patients treated with the 60/20 mg dose regimen compared with the 30/10 mg dose regimen (32% vs 44%), or in terms of the incidence of events rated as "severe," which were 11% in each group.
There did not seem to be any clinically significant trend differences in vital signs or laboratory test results, nor were any dose-dependent differences in laboratory test results noted among patients treated with PF-04494700. In addition, there were no consistent, dose-dependent differences in mean ECG parameters between patients administered PF-04494700 and placebo, including heart rate, mean PR interval, QRS duration, or QTc. However, 5 patients on the 60/20 mg regimen and 7 patients on the 30/10 mg regimen had maximum on-treatment changes in the QTcB of greater than 30 ms, and in 1 of these patients, the increase was greater than 60 ms. These results are consistent with transient increases in QTc reported in an earlier phase 1 study in which QTc prolongation was observed in dogs that were administered a dose of PF-04494700 greater than 10 mg/kg. Once, daily dosing with PF-04494700 resulted in mean trough plasma concentrations of PF-04494700 that were dose proportionately higher on the 20 mg maintenance dose compared with the 10 mg maintenance dose. On day 70, the mean PF-04494700 trough concentration was approximately 67% lower for male patients compared with female patients on both the 20 and 10 mg dose regimens. This finding needs to be replicated with larger sample sizes, and in a study designed for comprehensive evaluation of PK parameters.
The results for the secondary efficacy parameters were inconclusive. Ten weeks of treatment with PF-04494700 had no consistent effects on plasma levels of Ab or inflammatory markers (hs-CRP, IL-1, IL-6, isoprostanes, and TGF-b). For several measures, baseline values were in the normal or low-normal range. This coupled with large measurement variability, limited the ability to detect a treatment effect.
No meaningful treatment effect was observed at week 10 on PF-04494700 in secondary cognitive and functional measures, including MMSE, ADAS-Cog, ADCS-ADL, and CDR-Sum of Boxes. This was anticipated, based on the proposed mechanism: antiamyloid and anti-inflammatory effects may slow disease progression, but are not expected to have short-term effects on disease symptoms.
A potential limitation of this study was the absence of information on clinical variables that have been reported to influence the concentration of inflammatory markers, such as alcohol and smoking status, hormone replacement therapy, level of physical activity, etc.
In conclusion, 10 weeks of treatment of elderly AD patients with PF-04494700 was well tolerated, with no treatment emergent changes in laboratory, vital signs, or ECG parameters. PF-04494700 had no consistent or clinically meaningful effect on plasma levels of Ab, inflammatory biomarkers, or secondary cognitive or functional outcomes in this brief pilot study. Further studies are planned to assess the impact of long-term treatment on cognitive and clinical measures in patients with AD.
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